Immorta Bio’s nine-amino-acid peptide aims at zombie cells

Longevity.Technology is growing fast; we are open to conversations with prospective partners and investors who share our vision.

Please get in touch if you are interested:

Immorta Bio says its AI-designed SenoMune-0257 prompts T cells to clear senescent cells, and plans first human evaluation before year-end.

The molecule at the center of Immorta Bio’s latest announcement is just nine amino acids long, which is tiny by drug standards. On 12 October, the Miami company said it has completed planned preclinical studies for SenoMune-0257, a synthetic peptide designed to help the immune system recognize and eliminate senescent cells. Immorta says artificial intelligence helped identify it [1].

Create a free account to read this article now

Join the 12,000+ biotech, pharma and investment leaders who read Longevity.Technology. No password, no payment.

By continuing you agree to our Terms and Privacy Policy, and to receive the free Longevity.Technology newsletter. You can unsubscribe at any time.

LTUI: 3543

Immorta Bio

Longevity level(s):

  • Level 6: Aging disease prevention therapeutics
    Therapeutic interventions that control aging drivers to prevent aging diseases from occurring, like the current wave of GLP-1 agonists that prevent type 2 diabetes through metabolic interventions that also are proving effective in mitigating cardiovascular and neurological diseases.
  • Level 7: Targeted aging disease reversal
    Therapeutic interventions that stop or reverse age-related damage in specific organs (organ specific / tissue specific / localized reversal) or for age-related diseases including technologies like partial cellular reprogramming.
  • Level 8: Systemic aging reversal
    Therapeutic interventions that stop or reverse age-related damage throughout the whole body system at a cellular level. Including technologies such as mitochondrial transplant, senotherapeutics and partial cellular reprogramming.

Overview

Immorta Bio is a preclinical-stage longevity biotechnology company developing senescent cell immunotherapies and personalized stem cell treatments to address fundamental mechanisms of biological aging. The company's dual-platform approach combines SenoVax™, a first-in-class senolytic immunotherapy designed to eliminate aging cells and restore immune surveillance, with StemCellRevivify™, which utilizes personalized mesenchymal stem cells and progenitor cells to restore regenerative capacity. Immorta Bio targets multiple age-related pathologies including cancer, organ failure, neurodegeneration, and inflammatory diseases through mechanisms that address cellular senescence, stem cell exhaustion, and chronic inflammation.

Access all data points on DLT:

  • Financial Data
  • Patents
  • Technology
  • Management
  • Advisory Board
  • News
  • Classifications
  • Similar Companies
Expand

Kyle Umipig

Kyle has nine years of editorial writing experience. They have been following the longevity sector since 2022, focusing on research, emerging tech, and the companies shaping the future of aging and age-related health.

Sign up for our daily newsletter to get our biggest longevity stories, handpicked for you each day.

The latest longevity science, investment, innovation and insight, delivered every morning.

Unlock Longevity Biotech Report for FREE